Evolent Health Raises 2026 Adjusted EBITDA Forecast to $130M-$135M
Evolent renewed its largest Surgical Management customer contract for four years and reported two new revenue agreements, bringing its year-to-date total to seven new or renewed contracts. The company reiterated 2026 revenue guidance of $2.6 billion to $2.7 billion and expects $26 million to $28 million in capitalized expenditures.
Evolent Health announced the renewal of its largest Surgical Management customer contract for an additional four years, noting that this business was acquired through the IPG acquisition in 2022. The company also reported two new revenue agreements, bringing its year-to-date total to seven new or renewed contracts. Management highlighted that demand for its specialty care solutions remains robust as health plans seek to balance affordability with patient and provider experience. Additionally, the company reiterated its 2026 revenue guidance of $2.6 billion to $2.7 billion and raised its Adjusted EBITDA forecast to a range of $130 million to $135 million.
Evolent also expects to deploy $26 million to $28 million in cash for capitalized expenditures during the year.